Clinical TrialAug 4, 2026, 06:58 AM
Rhythm Pharma RM-718 Phase 2 Shows -11.6% BMI Reduction in HO
AI Summary
Rhythm Pharmaceuticals announced encouraging preliminary Phase 2 trial results for RM-718, its investigational once-weekly MC4R agonist, in patients with acquired hypothalamic obesity (HO). The trial showed a mean BMI reduction of -11.6% at Week 16, consistent with previous treatments setmelanotide and bivamelagon, with limited hyperpigmentation. The company will host a conference call to discuss these results and its second quarter 2026 financial results.
Key Highlights
- RM-718 showed an -11.6% mean reduction in BMI from baseline at Week 16 (n=7) in acquired HO patients.
- Efficacy results for RM-718 at 16 weeks were comparable to setmelanotide (-10.1% BMI reduction at 16 weeks, n=64).
- RM-718 efficacy was also comparable to bivamelagon (-10.1% BMI reduction at 14 weeks, n=7).
- Only two mild instances of hyperpigmentation were reported, limited to the injection site.
- RM-718 was generally well tolerated; common adverse events included injection site reactions, nausea, and vomiting.
- Two patients discontinued treatment due to adverse events (injection site induration and nausea).
Price Impact
More from RYTM